Abstract Effective combined antiretroviral therapy (cART)
Introduction
HIV-associated neurocognitive disorders (HAND) are a significant, life-altering complication of HIV infection that can persist even when viremia is suppressed by combination antiretroviral therapy (cART) (Simioni et al. 2010) . HAND encompasses a spectrum of disorders ranging from asymptomatic neurocognitive impairment (ANI), which does not affect the patient's daily function, to mild neurocognitive disorder (MND), which affects the patient's daily function at work, school, or home, to HIV-associated dementia (HAD), which is a highly debilitating, frank dementia (Antinori et al. 2007) . Although modern cART regimens have decreased the prevalence of HAD, the prevalence of the more minor conditions (ANI and MND) has increased, thus maintaining the prevalence of HAND around 50 % in the HIV-infected population (Ances and Ellis 2007; Heaton et al. 2010) . Despite many years of investigation and many clinical trials, no treatment for HAND exists.
Given the need for neuroprotective compounds to treat HAND, an in vitro drug screen was used to identify compounds that would protect mixed hippocampal cultures from HIV gp120 and Tat neurotoxicity (Nath et al. 2012) . Fluconazole, an antifungal, and paroxetine, a selective serotonin reuptake inhibitor (SSRI), proved neuroprotective in this screen. These drugs were attractive neuroprotective agents because they are already approved for long-term use in humans and are well tolerated for prolonged use.
Paroxetine was particularly appealing for HAND treatment because of a study by Letendre and colleagues , who demonstrated that patients taking selective serotonin reuptake inhibitors were less likely to have detectable viral loads in the CSF and performed better in neuropsychological testing (Letendre et al. 2007 ). Additionally, SSRIs or serotonin alone, have been neuroprotective in animal models of Parkinson's disease, Alzheimer's disease, and Huntington's disease (Chiou et al. 2006; Chung et al. 2010 Chung et al. , 2011 Mattson et al. 2004; Nelson et al. 2007; Peng et al. 2008; Shibui et al. 2009 ). Most relevant to this study, Lee and colleagues showed that paroxetine reversed the loss of amplifying neuroprogenitor cells in the hippocampus of gp120 transgenic mice (Lee et al. 2011 ). Furthermore, SSRIs or serotonin alone inhibited HIV replication in vitro in both cell lines and primary monocyte-derived macrophages (Benton et al. 2010; Kristiansen and Hansen 2000; Maneglier et al. 2008) , which belong to the same family of cells as perivascular macrophages and microglia, the productively infected cells in the CNS.
The in vitro drug screen data together with the literature on SSRI neuroprotection and inhibition of HIV replication inspired both the preclinical evaluation of potential protective effects of fluconazole and paroxetine in an accelerated, consistent SIV/pigtailed macaque model of HIV-associated CNS disease and a phase I/II human clinical trial, which is currently enrolling participants. Using the SIV model of HIV-associated CNS disease, we found FluPar treatment to be protective against neurodegeneration without blunting neuroinflammation or viral replication in the CNS or plasma.
Methods

Cell culture
Neuronal cultures from rodent hippocampus were prepared from embryonic day 18 Sprague-Dawley rats using methods similar to those described previously (Haughey et al. 2004 ). Tissues were dissociated by gentle trituration with a firepolished glass pipette in calcium-free Hank's balanced salt solution. The single cell suspension was centrifuged at 1,000g and re-suspended in minimal essential medium containing 10 % heat-inactivated fetal bovine serum and 1 % (v/v) antibiotic and antimycotic solution (penicillin G 104 units/mL, streptomycin 10 mg/mL, and amphotericin B 25 mg/mL; Sigma; St. Louis, MO). Cells were allowed to attach for 3 h before the media was replaced with serum-free neurobasal medium containing 2 % (v/v) B-27 supplement (Gibco; Rockville, MD) and 1 % (v/v) antibiotic and antimycotic mix (Sigma). Rat mixed hippocampal neurons were generated from freshly cultured rat hippocampi in neurobasal media containing 5 % (v/v) fetal bovine serum and 2 % (v/v) B27 supplement. Hippocampal neurons were plated in 96-well plates at a density of 4×10 5 cells/mL for neurotoxicity studies.
Compound screening
The Microsource Discovery Spectrum Collection of compounds contains 2,000 compounds, of which about half are FDA-approved drugs and the remaining compounds are natural products or other compounds with some prior human exposure and safety testing data. The compound collection is dispensed and maintained on 96-well plates at a concentration of 10 mM in 100 % DMSO and stored at −80°C. The compound mother plates were thawed one time in order to make four sets of daughter plates, and one set of daughter plates was used for these screening assays. Previously, a total of 2,000 compounds were screened using the oxidative stressor 3-nitropropionic acid (3-NP) neurotoxicity assay in rat mixed hippocampal cultures, with screening at 10 uM drug concentration against the toxic effects of 3 mM 3-NP for 24 h (Nath et al. 2012) . From these screening assays, 256 compounds showed >50 % protection. Additionally, of these "hits," 146 compounds displayed complete (100 % protection) and 53 demonstrated >200 % protection. We then tested the efficacy of these compounds for neuroprotection against HIV gp120 and Tat by measuring cell survival using the MTT assay as described previously (Nath et al. 2012 ).
Cell survival assay
Neuronal cell viability was assessed with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. This assay (Mosmann 1983 ) is based on the ability of a mitochondrial dehydrogenase enzyme from viable cells to cleave the tetrazolium rings of the pale yellow MTT and form dark blue formazan crystals. These crystals are largely impermeable to cell membranes, and thus accumulate within healthy cells. The resultant formazan precipitates are solubilized with dimethyl sulfoxide (DMSO) and read on a multiwell scanning spectrophotometer (SpectraMAX M5e, Molecular Devices). The number of surviving cells is directly proportional to the level of the formazan product created.
Animal infection and treatment
Pigtailed macaques (Macaca nemestrina) were used for these studies. Prior to inoculation, blood and CSF were collected at least three times, at least 2 weeks apart, under ketamine anesthesia, to establish baseline levels of several parameters. Six macaques were mock-inoculated procedural controls. Twenty-one macaques were co-inoculated intravenously with an immunosuppressive swarm (SIV/DeltaB670) and a neurovirulent clone (SIV/17E-Fr) of SIV (Zink et al. 1999) . Fifteen SIV-infected macaques remained untreated and six were treated orally with a combination of fluconazole (12.5 mg, once daily) and paroxetine (5 mg, once daily) beginning at 12 days of postinoculation (dpi) and continuing until euthanasia. SIV-infected macaques were scheduled for euthanasia at approximately 84 dpi, the time at which all animals have AIDS and most have developed encephalitis in this model (Clements et al. 2008; Zink et al. 1999) . If an animal developed clinical symptoms, as described previously (Weed et al. 2003) , prior to the scheduled euthanasia date, the animal was humanely euthanized. Blood and CSF were collected at days 7, 10, 14, 21, and 28 dpi, every 2 weeks thereafter, and at euthanasia. At euthanasia, the macaques were perfused with PBS under barbiturate anesthesia to remove blood from the vasculature. The brain was sliced in 0.5 cm coronal sections. Portions of the brain and other tissues were snap frozen then stored at −80°C until use, while other portions were fixed and paraffin embedded. The Johns Hopkins Animal Care and Use Committee approved all animal studies. Animals were treated humanely in accordance with federal guidelines. SIV RNA measurement in plasma, CSF, and brain by qRT-PCR SIV RNA was measured in plasma, CSF, brain and spleen by qRT-PCR as described previously (Meulendyke et al. 2012) . SIV RNA levels were expressed as copy equivalents per milliliter of plasma/CSF or per microgram tissue RNA. Statistical analyses of viral loads were performed on logtransformed values.
CCL2 and IL-6 measurement by ELISA CCL2 and IL-6 were measured by ELISA in CSF collected at various points throughout infection from SIV-infected, untreated, and FluPar-treated macaques as described previously (Mankowski et al. 2004 ).
Immunohistochemistry neuronal damage and neuroinflammatory markers Amyloid precursor protein (APP) accumulates in damaged axons and therefore was quantified in the long white matter tracts of the corpus callosum. Immunohistochemical staining and quantitation of APP was performed as described previously (Mankowski et al. 2002b ). Quantitative immunohistochemistry for the neuroinflammatory markers CD68 (marker of macrophage/microglial activation) and MHC class II (marker of macrophage/microglial and endothelial cell activation) was performed on deep white matter, adjacent to the basal ganglia as described previously (Clements et al. 2002; Zink et al. 2001) . Quantitation of all these markers was performed as described previously, with the exception that the microscope, camera, and software were Nikon Eclipse 90i (microscope) with motorized stage, Nikon DS-Ri1 (camera), and NIS Elements AR (software; all microscopy tools from Nikon; Melville, NY).
Neurofilament light chain measurement by ELISA
The presence of neurofilament light chain in the CSF indicates neuronal damage in several neurodegenerative diseases, including HIV (Abdulle et al. 2007; Jessen Krut et al. 2014; Norgren et al. 2003; Rosengren et al. 1996) . Neurofilament light chain was measured in CSF from SIV-infected, untreated and SIV-infected, FluPar-treated macaques using a highly sensitive, commercially available ELISA (IBL International; Toronto, ON). Data were expressed as fold change in CSF sampled prior to euthanasia compared to preinoculation levels.
CaMKIIα detection by Western blotting
Samples from frontal cortex gray matter of uninfected, SIVinfected, untreated and SIV-infected, FluPar-treated macaques were homogenized in 0.5 % NP-40 lysis buffer containing protease inhibitor cocktail (Sigma), insoluble debris was removed by centrifugation, and protein was quantitated using the BioRad Protein Assay Kit (BioRad; Hercules, CA). Twenty-five micrograms of protein per sample were resolved under reducing conditions using 10 % Bis-Tris gels and MOPS buffer and then transferred to PVDF membranes. Membranes were blocked in Tris-buffered saline Tween-20 (TBST) (20 mM Tris, 137 mM NaCl, pH 7.5, 0.1 % Tween-20) containing 5 % nonfat dry milk then probed using rabbit anti-CaMKII (pan) primary antibodies (1:1,000, Cell Signaling Technology; Danvers, MA) diluted in TBST containing 5 % bovine serum albumin (BSA) for 2 days at 4°C. Membranes were washed with TBST then probed with goat anti-rabbit-HRP antibodies (1:10,000; Dako; Glostrup, Denmark) diluted in 5 % BSA-TBST, washed, then finally developed with Super Signal West Dura Substrate (Thermo Fisher Scientific; Waltham, MA). The CaMKα isoform was distinguished from other isoforms by molecular weight (~50 kDa). Membranes were then probed using mouse anti-ß-actin primary antibodies (1:5,000; Sigma-Aldrich) diluted in 5 % BSA-TBST. Membranes were washed with TBST then probed with goat anti-mouse-HRP antibodies (1:10,000; Dako) diluted in 5 % BSA-TBST, washed, then finally developed with Super Signal West Pico Substrate (Thermo Fisher Scientific). Images of the films were digitally scanned then quantitated using ImageQuant TL 7.0 software (Amersham; Piscataway, NJ). To normalize each sample for protein loading, CaMKIIα was normalized to ß-actin. The experiment was performed in triplicate. To account for blotto-blot variation, the CaMKIIα/ß-actin ratio of each sample was normalized to one of the uninfected controls and the final quantitation represented the average of the triplicates.
Striatal serotonin measurement by ELISA Striatal samples were weighed, diluted 1/20 (w/v) in 0.1 % ascorbic acid, and homogenized by sonication. Insoluble debris was removed by centrifugation and serotonin was measured using an ultrasensitive ELISA according to the manufacturer's protocol (Eagle Biosciences; Nashua, NH). Data were expressed as nanogram serotonin per milligram tissue.
Neopterin measurement by ELISA Neopterin, a marker of macrophage/microglial activation, was measured in CSF from SIV-infected, untreated and SIV-infected, FluPar-treated macaques using a commercially available ELISA (IBL International; Toronto, ON). Data were expressed as fold change in CSF sampled prior to euthanasia compared to preinoculation levels.
IDO mRNA measurement by qRT-PCR Total RNA was isolated from macaque parietal cortex and indoleamine 2,3-dioxygenase (IDO) messenger RNA (mRNA) and 18S RNA were measured by multiplexed qRT-PCR as described previously (Zink et al. 2010 ) using a RotorGene Q thermocycler (Qiagen). IDO mRNA was normalized to 18S RNA and expressed as fold change compared to the median SIV-infected, untreated, using the ΔΔCt method. For samples with undetectable levels of IDO mRNA, the IDO Ct was set to the highest detectable Ct+3.57 cycles, which would be approximately tenfold lower level of IDO mRNA than the lowest detectable level. The ΔΔCt for all samples with undetectable IDO was set to lowest undetectable ΔΔCt.
Statistical analyses
For in vitro drug screening assays, all data are represented as mean±SEM and analyzed by one-way analysis of variance (ANOVA). Group-wise post hoc comparisons were assessed by Newman-Keuls multiple comparison tests.
For in vivo data, group vs. group (SIV-infected, untreated vs. SIV-infected, FluPar-treated) statistical comparisons were made using the Mann-Whitney test, the nonparametric equivalent of the Student's t test. For measurements taken longitudinally throughout SIV infection (i.e., plasma/CSF viral loads, CCL2 CSF levels, and IL-6 CSF levels), three statistical questions were asked: (1) Were the two groups (SIV-infected, untreated and SIV-infected, FluPar-treated) different just prior to FluPar treatment (initiated at 12 dpi)? For this group vs. group comparison, a Mann-Whitney test was performed on the data at 10 dpi (log 10 transformed values for viral load or, fold change at 10 dpi compared to preinoculation for CCL2 and IL-6 levels in the CSF). (2) Did FluPar treatment have a rapid impact on the variable (change from 10 to 21 dpi, the end of the acute phase of disease and the beginning of the asymptomatic/chronic phase of disease)? The fold change from 21 vs. 10 dpi was calculated for each macaque and for comparison of groups the Mann-Whitney test was performed. (3) Did FluPar impact the variable during the chronic phase of the disease? Change over time from 21 dpi until euthanasia was measured by a linear regression model for longitudinal data (repeated measurements over time), whereby group vs. group comparisons tested the differences in slopes (coefficients of the "dpi" variable). For viral loads, log 10 transformed values were used. For CCL2 and IL-6 levels in the CSF, the fold change compared to preinoculation level was used. For all statistical analyses, the significance level was set at p<0.05.
Results
Fluconazole and paroxetine were neuroprotective against HIV gp120 and Tat toxicity
The Microsource Discovery Spectrum collection of compounds contains 2,000 FDA approved drugs and other naturally occurring compounds. We screened the entire library at a single concentration of 10 μM of each compound and found that more than 256 compounds demonstrated >50 % protection (Nath et al. 2012) . The antidepressant paroxetine and the antifungal fluconazole were among these active neuroprotective compounds, with neuroprotection against oxidative stress confirmed in a secondary assay. In order to utilize these compounds as potential adjunctive neuroprotective therapies against HAND, we evaluated the effects of both compounds as protectants against the HIV viral toxic proteins gp120 and Tat (Fig. 1) . Both paroxetine and fluconazole displayed concentration dependent neuroprotective actions against both viral proteins, with paroxetine protective at 100-500 nM, while fluconazole had significant neuroprotection at 1-5 uM concentrations. These are drug concentrations that have been found in the CNS of drug-treated patients (Henry et al. 2000; Thaler et al. 1995) .
FluPar treatment reduced SIV-induced neurodegeneration
Given the protective effects of fluconazole and paroxetine on HIV gp120 and Tat neurotoxicity in vitro, we tested the neuroprotective effects of combination fluconazole/ paroxetine (FluPar) treatment in a SIV model of HIVassociated CNS disease. Pigtailed macaques were dually inoculated with an immunosuppressive swarm (SIV/ DeltaB670) and a neurovirulent clone (SIV/17E-Fr) of SIV, then either left untreated or treated with a combination fluconazole and paroxetine (FluPar) beginning at 12 dpi until euthanasia, approximately 84 dpi.
To assess the neuroprotective effect of FluPar treatment, we examined three indicators of neurodegeneration: CSF neurofilament light chain levels, APP accumulation in axons, and tissue levels of CaMKIIα. The presence of neurofilament light chain in the CSF is indicative of neuronal damage, particularly axonal damage, in several neurodegenerative diseases, including HIV (Abdulle et al. 2007; Jessen Krut et al. 2014; Norgren et al. 2003; Rosengren et al. 1996) . FluPar-treated macaques had significantly lower levels of neurofilament light chain in the CSF compared to SIV-infected, untreated macaques ( p= 0.023; Fig. 2a) .
We previously demonstrated axonal accumulation of APP in our SIV macaque model, which was highly correlative with behavioral deficits (Mankowski et al. 2002b; Weed et al. 2003) . We found that FluPar-treated macaques had significantly lower levels of APP accumulation than SIV-infected, untreated macaques ( p=0.041; Fig. 2b ).
CaMKIIα is a synaptodendritic kinase important for learning and memory (Coultrap and Bayer 2012; Frankland et al. 2001; Lisman et al. 2012 ). We previously showed CaMKII or Tat (b and d), then assayed for cell viability using the MTT assay. Data are represented as mean±SEM and analyzed by one-way analysis of variance (ANOVA). Group-wise post hoc comparisons were assessed by Newman-Keuls multiple comparison tests. *p<0.05; **p<0.01; ***p<0.001 dysregulation in the hippocampus and frontal cortex of SIVinfected rhesus macaques (Macaca mulatta) (Gupta et al. 2010) . In collaboration with the Jordan-Sciutto lab, we recently showed lower levels of CaMKIIα in the frontal cortex of SIV-infected macaques treated by combination antiretroviral therapy (cART) compared to both uninfected and SIVinfected, untreated controls (Akay et al. 2014) . In this study, Western blotting demonstrated that FluPar-treated macaques had higher levels of CaMKIIα than the untreated controls (p= 0.004; Fig. 3 ). Together, these data indicate that FluPar treatment protected macaques from SIV-induced neurodegeneration based on several indicators of neuronal integrity.
FluPar treatment did not affect plasma or CSF viral loads SIV viral loads were measured throughout infection in the plasma and CSF of SIV-infected macaques that were either untreated or treated with FluPar beginning at 12 dpi. FluPar treatment did not significantly impact plasma or CSF viral loads either soon after treatment initiation (fold change of 21 dpi compared to peak at 10 dpi) or during the chronic phase of disease from 21 dpi until euthanasia (Fig. 4) . Untreated macaques had slightly higher plasma and CSF viral loads at 10 dpi than FluPar-treated macaques, but the slope of viral RNA levels for the two groups did not differ after treatment initiation.
FluPar treatment did not affect SIV replication in the brain SIV replication in the brain was measured by qRT-PCR in both the basal ganglia and parietal cortex. Median viral loads in the basal ganglia and parietal cortex were lower in FluPartreated macaques than uninfected controls, but the differences were not statistically significant ( p=0.299 and p=0.777, respectively; Fig. 5 ). If there were small differences in brain viral loads, a larger sample size would be needed to detect the difference.
Effect of FluPar treatment on brain serotonin levels
Both SIV and HIV infection have been shown to decrease levels of serotonin in the striatum (Drewes et al. submitted; Reynolds and Sardar 1996) . The paroxetine component of FluPar treatment is an SSRI. Therefore, we expected FluPartreated macaques to have higher levels of serotonin than untreated macaques. FluPar-treated macaques tended to have Fig. 2 FluPar treatment reduced neuronal damage. Neurofilament light chain was measured in the CSF preinoculation and just prior to euthanasia by ELISA. Data are expressed as fold change at euthanasia compared to preinoculation levels. FluPar-treated macaques had significantly lower levels of neurofilament light chain in the CSF at euthanasia compared to controls (p=0.023; a). APP was measured in the corpus callosum using quantitative immunohistochemistry as a marker of axonal degeneration. FluPar-treated macaques had significantly lower levels of APP than untreated controls (p=0.041, b). Bars represent medians. Statistical comparisons were made using the Mann-Whitney test Fig. 3 FluPar treatment prevented SIV-induced CaMKIIα loss in the frontal cortex. CaMKIIα was measured in frontal cortex homogenates by Western blotting and normalized to ß-actin to control for protein loading. FluPar-treated macaques had significantly higher levels of CaMKIIα in the frontal cortex than untreated controls (p=0.004). Bars in b represent medians. Statistical comparisons were made using the Mann-Whitney test higher levels of striatal serotonin than untreated controls; however, this did not quite reach statistical significance ( p= 0.076; Fig. 6 ). (Mankowski et al. 2002a ). The encephalitis is accompanied and/or mediated by a predictable, well-documented neuroinflammatory cascade. FluPar's effect on SIV-induced neuroinflammation was measured using several methods. CCL2 and IL-6 levels in the CSF are early predictive indicators of which macaques will develop encephalitis (Mankowski et al. 2004; Zink et al. 2001) . CSF was collected periodically throughout infection and levels of CCL2 and IL-6 were measured by ELISA. FluPar treatment did not significantly impact levels of CCL2 or IL-6 in the CSF either soon after treatment initiation (fold change of 21 dpi compared to peak at 10 dpi) or the chronic progression from 21 dpi until euthanasia (Fig. 7a, b) . To examine neuroinflammation in brain tissue, we used quantitative immunohistochemistry to measure markers of activated macrophages/microglia (CD68 and MHC class II) in the subcortical white matter adjacent to the basal ganglia. Although the median level of CD68 and MHC class II staining was lower in the FluPar-treated macaques than untreated controls, the difference was not statistically significant ( p= 0.197 and p=0.387, respectively; Fig. 7c, d ). Macrophage activation was also assessed by measuring the small molecule, neopterin, in the CSF. Neopterin is produced by macrophages subjected to proinflammatory stimuli, such as interferon gamma, and is elevated in the CSF of HIV-infected individuals, even in the setting of cART (Hagberg et al. 2010) . FluPartreated macaques did not have significantly different levels of neopterin in the CSF than their untreated counterparts ( p= 0.788; Fig. 7e ). Indoleamine 2,3-dioxygenase (IDO) is tryptophan-catabolizing enzyme induced by type I and II interferons, which can contribute to immune dysregulation, oxidative stress, and neuronal dysfunction. IDO is elevated in both SIV and HIV CNS disease (Burudi et al. 2002; Drewes et al. submitted; Sardar and Reynolds 1995) . We measured IDO mRNA in the parietal cortex of both SIV-infected, untreated macaques and SIV-infected, FluPar treated macaques and found that FluPar treatment had no significant impact ( p= 0.603; Fig. 7f ). Taken together these data demonstrate that FluPar treatment had no significant effect on SIV-induced neuroinflammation in this model. Fig. 4 FluPar treatment had no effect on plasma or CSF viral loads. Viral RNA in plasma (a) and CSF (b) was quantitated in samples collected throughout infection by qRT-PCR. Arrow indicates time of treatment initiation (12 dpi). Asterisk indicates p<0.05, Mann-Whitney comparison. Other statistical comparisons made using these longitudinally measured data are described in detail in the methods. 
FluPar treatment did not affect SIV-induced neuroinflammation SIV encephalitis is a pathological hallmark of SIV infection of the CNS that closely reflects HIV CNS infection
Discussion
Combination fluconazole/paroxetine (FluPar) treatment prevented neurodegeneration in an accelerated, consistent SIV/macaque model of HIV-associated CNS disease without significantly impacting neuroinflammation or viral replication, which is a unique mode of protection for HAND. The drugs were selected based on results from a unique drug screen designed to measure protection against HIV gp120 and Tat neurotoxicity in a primary mixed hippocampal cell culture system, which inspired not only this study, but also an ongoing clinical trial.
In our SIV/macaque model of HIV-associated CNS disease, FluPar treatment protected against neurodegeneration as determined by three separate measures. First, FluPar treatment reduced the level neurofilament light chain in the CSF. Neurofilament light chain is an important structural component of axons and is elevated in the CSF of patients with neurodegenerative diseases with wide-ranging etiologies, such as Alzheimer's disease, amyotrophic lateral sclerosis, cerebral infarction, multiple sclerosis, Parkinson's disease, and HIV (Abdulle et al. 2007; Jessen Krut et al. 2014; Norgren et al. 2003; Rosengren et al. 1996) . Second, FluPar treatment prevented axonal APP accumulation, supporting the neurofilament light chain data indicating protection from axonal damage. APP is most commonly recognized as the precursor to Aß, a major component of senile plaques characteristic of Alzheimer's disease. APP accumulates in damaged axons and has been shown to accumulate both in the brains of SIV-infected macaques and HIV-infected humans (Giometto Fig. 6 SIV-infected, FluPar-treated macaques had higher median levels of striatal serotonin than SIV-infected, untreated macaques (p=0.078). Serotonin in the striatum was measured by ELISA. Bars represent medians. Statistical comparisons were made using the Mann-Whitney test Neopterin levels in the CSF were measured by ELISA (e). IDO mRNA in the parietal cortex was measured by qRT-PCR (f). Bars in c-f represent medians. Statistical comparisons made using longitudinally measured data in a and b are described in detail in the methods. Statistical comparisons in c-f were made using the Mann-Whitney test et al. 1997; Mankowski et al. 2002b) . Finally, FluPar treatment prevented CaMKIIα loss, indicating protection from synaptodendritic damage. CaMKIIα is important for learning and memory (Coultrap and Bayer 2012; Frankland et al. 2001; Lisman et al. 2012) . Therefore, any changes in levels or activation could have significant cognitive consequences. We previously showed alterations in CaMKIIα in both the pigtailed macaque (M. nemestrina) model used in this study and the less pathogenic rhesus macaque (M. mulatta) model (Akay et al. 2014; Gupta et al. 2010) . In contrast to the pigtailed macaque model, total levels of CaMKIIα were unchanged while CaMKIIα activation was decreased in SIVinfected rhesus macaques, indicating that SIV-induced disruption of CaMKIIα could be species-specific, model-specific, and disease stage-specific. CaMKIIα alterations have not yet been reported in human brains; however, rat hippocampal cultures exposed to supernatants from HIV-infected human monocyte-derived macrophages had decreased CaMKIIα activation (Gupta et al. 2010) , indicating that HIV can cause CaMKIIα dysregulation.
Further studies will be needed to parse out the individual neuroprotective contributions of fluconazole and paroxetine and to dissect the molecular mechanisms of protection against SIV/HIV-induced neurodegeneration. There are currently no published reports on the neuroprotective capabilities of fluconazole, so we cannot speculate on its mechanism of neuroprotection, although there is evidence that it may reach therapeutic levels in the brain (Thaler et al. 1995) . In contrast, paroxetine and other SSRIs have proven neuroprotective in several animal models of neurodegenerative diseases (Chiou et al. 2006; Chung et al. 2010; Chung et al. 2011; Lim et al. 2009; Mattson et al. 2004; Nelson et al. 2007; Peng et al. 2008; Shibui et al. 2009 ). SSRI neuroprotection has been attributed to inhibition of neuroinflammation and oxidative stress (Chiou et al. 2006; Chung et al. 2010; Chung et al. 2011; Lim et al. 2009; Zhang et al. 2012) , inhibition of apoptosis and promotion of neuroprotective BDNF signaling , rescue or enhancement of neurogenesis (Jiang et al. 2014; Klomp et al. 2014; Lee et al. 2011; Stagni et al. 2013) , and even inhibition of glutamate excitotoxicity (Vizi et al. 2013) in both animal models and cell culture, all of which have been implicated in the development of HAND (Lindl et al. 2010; Mocchetti et al. 2014; Potter et al. 2013; Steiner et al. 2006) . In this study, we found FluPar treatment prevented neurodegeneration without significantly inhibiting multiple measures of neuroinflammation, indicating further investigation into the mechanism of action is needed.
It is unclear whether paroxetine's neuroprotective effects in this SIV model of HIV-associated CNS disease could be due to its effects on serotonin or other novel mechanisms of action. In this study, FluPar-treated macaques showed a trend toward increased striatal serotonin levels that did not quite reach statistical significance (Fig. 6 ). Because we measured total tissue levels of serotonin, it is possible that FluPar treatment could have elevated synaptic serotonin, thereby facilitating neuroprotection. Alternatively, FluPar neuroprotection could be afforded by a heretofore unidentified mechanism. In a MPTP mouse model of Parkinson's disease, the SSRI fluoxetine prevented neuroinflammation and dopaminergic neuron loss without affecting striatal serotonin levels, indicating that tissue serotonin levels may not correspond with neuroprotection (Chung et al. 2011) .
Neuroinflammation and viral replication are important mediators in HIV/SIV CNS disease (Gonzalez-Scarano and Martin-Garcia 2005) . Paroxetine, other SSRIs, and serotonin itself have been shown to inhibit HIV replication in vitro in both cell lines and primary monocyte-derived macrophages (Benton et al. 2010; Kristiansen and Hansen 2000; Maneglier et al. 2008) . Furthermore, Letendre and colleagues showed HIV-infected patients taking SSRIs were less likely to have detectable viral loads in the CSF (Letendre et al. 2007 ), so we were disappointed that FluPar treatment did not improve plasma, CSF, or brain tissue SIV viral loads. However, it was important to find that viral loads were not elevated by FluPar treatment, which would contraindicate its use for HIV, regardless of neuroprotection.
The neuroprotective results of this SIV/macaque study heighten enthusiasm for the ongoing clinical trial testing the efficacy of combination fluconazole/paroxetine treatment in patients with HAND, which was inspired by the same in vitro drug screen data in Fig. 1 . There are important differences in study design, outcome measures, and benefits vs. limitations between the SIV/macaque study presented here and the human clinical trial underway. In this SIV/macaque study, macaques were administered FluPar daily beginning at 12 dpi, at the end of the acute phase of disease. In contrast, patients enrolled in the human clinical trial have already developed HAND, and therefore are in a more advanced stage of disease. In our study, it is likely that FluPar treatment prevented neurodegeneration because it was administered early in infection, and it is not known whether FluPar will reverse neurodegeneration in patients that have already developed HAND. A study using the gp120 transgenic mouse model found that paroxetine rescued gp120-induced deficiencies in hippocampal neurogenesis, indicating paroxetine has the potential to reverse some kinds of neurological damage (Lee et al. 2011) . In this SIV/macaque study, we also measured different disease outcomes than are planned for the human clinical trial. The SIV/macaque model has the advantage of extensive tissue sampling, so in addition to measuring markers of disease progression in plasma and CSF, we were able to measure these markers directly in tissues, which is not possible in human patients. Of the three neurodegenerative parameters which were protected by FluPar treatment, only neurofilament light chain in the CSF can be measured in human patients, and we would recommend the investigators involved in the clinical trial do so, if sample availability permits. The human clinical trial has the advantage of measuring neurocognitive outcomes, which is cost-prohibitive in the SIV/macaque model. Another benefit of the human clinical trial is its placebocontrolled 2×2 factorial design whereby patients will receive (1) placebo, (2) fluconazole alone, (3) paroxetine alone, or (4) combination fluconazole/paroxetine, which will help discern individual drug effects. For these reasons, we are optimistically awaiting the outcome of the human clinical trial.
The finding that FluPar treatment protected SIV-infected macaques from neurodegeneration, despite ongoing neuroinflammation and viral replication has important implications in light of emerging latency reversing HIV eradication strategies. In these strategies, HIV-infected reservoirs are purged by reactivating latently infected cells, which are subsequently killed by cytotoxic T cells or cytopathic effects while cART prevents new rounds of infection (Margolis 2014; Xing and Siliciano 2013) . In addition to inducing viral replication, reversing latency will likely trigger inflammatory cascades. Because many antiretroviral drugs have low blood brain barrier penetration (Letendre et al. 2008 ), viral replication, and neuroinflammation after latency reversal could smolder, causing neurodegeneration. There may be a need for adjunct therapies, such as FluPar, that could prevent neurodegenerat i o n e v e n i n t h e f a c e o f v i r a l re p l i c a t i o n a n d neuroinflammation.
Finally, these studies highlight the importance of collaborative efforts to merge drug discovery and preclinical testing facilitated by initiatives such as the NIMH Center for Novel Therapeutics of HIV-associated Cognitive Disorders. Through these collaborative initiatives, we are hopeful that more potential therapies can be brought through the pipeline of discovery, to preclinical testing, and finally to the clinic to treat HAND as the disease currently stands and in the emerging frontier of HIV eradication.
